The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine
- PMID: 24425421
- PMCID: PMC4476262
- DOI: 10.1007/s12015-013-9487-7
The current status of iPS cells in cardiac research and their potential for tissue engineering and regenerative medicine
Abstract
The recent availability of human cardiomyocytes derived from induced pluripotent stem (iPS) cells opens new opportunities to build in vitro models of cardiac disease, screening for new drugs, and patient-specific cardiac therapy. Notably, the use of iPS cells enables studies in the wide pool of genotypes and phenotypes. We describe progress in reprogramming of induced pluripotent stem (iPS) cells towards the cardiac lineage/differentiation. The focus is on challenges of cardiac disease modeling using iPS cells and their potential to produce safe, effective and affordable therapies/applications with the emphasis of cardiac tissue engineering. We also discuss implications of human iPS cells to biological research and some of the future needs.
Conflict of interest statement
References
-
- Evans MJ, Kaufman MH. Establishment in culture of pluripotential cells from mouse embryos. Nature. 1981;292(5819):154–156. - PubMed
-
- Thomson JA, Itskovitz-Eldor J, Shapiro SS, et al. Embryonic stem cell lines derived from human blastocysts. Science. 1998;282(5391):1145–1147. - PubMed
-
- Shibata N, Umesono Y, Orii H, Sakurai T, Watanabe K, Agata K. Expression of vasa(vas)-related genes in germline cells and totipotent somatic stem cells of planarians. Developmental Biology. 1999;206(1):73–87. - PubMed
-
- Seydoux G, Braun RE. Pathway to totipotency: Lessons from germ cells. Cell. 2006;127(5):891–904. - PubMed
Publication types
MeSH terms
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
